The Alabama Poison Information Center has seen a major increase in calls relating to GLP-1 medications. Ozempic, Mounjaro, ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

Discover how obesity drugs may reduce alcohol consumption alongside weight loss. Learn about this promising new research.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on w ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

This study explores Lexaria's patented technology, DehydraTECH(TM), and its potential in addressing diabetes and weight ... focus on glucagon-like peptide 1 (“GLP-1”) drugs, liraglutide ...

The company cites Revita as an “off-ramp” to injectable GLP-1 treatments for obesity and diabetes. Fractyl’s shift in priorities means it is pausing development of Revita and its associated REVITALIZE ...